About HOPO Therapeutics

We envision a world where lead poisoning is treatable. Where children can safely grow up in an older home with lead paint or pipes, and women no longer need to fear the possibility of passing their own past exposure to their children. Where the transgenerational consequences of lead poisoning cease to plague low-income and vulnerable communities around the world.

Our mission is to improve the lives and futures of children, families, and communities living with the effects of lead poisoning. We accomplish this through breakthrough advances in science, and the development of innovative therapeutics specifically designed to provide safe, durable treatment for heavy metal poisoning.

We are uncompromising on our core values: that our science be exceptional, our treatments be accessible across the world, and that our patients always remain at the forefront of everything we do. We believe that no child should be disadvantaged simply by the quality of their water, the age of their home, or their proximity to industrial pollutants.

We are a mission-driven therapeutics company, committed to working with patients, physicians, and environmental experts to improve health around the world.

Who We Are

We possess an exceptional understanding of the behavior of heavy metals in the body, unmatched expertise with the investigational drugs at the core of our technology portfolio, and deep knowledge of business strategy in the life sciences and pharmaceutical industry. We have an unwavering commitment to the vision, mission, and values of the company.



Julian Rees, Ph.D.

Co-Founder, President and CEO


Hannah Weber

Vice President, Strategy & Business Development

Frequently Asked Questions

  1. What is HOPO-001? What does it do?
    The investigational drug HOPO-001 contain the active pharmaceutical ingredient 3,4,3-LI(1,2-HOPO), a metal chelator. It has been specifically designed to selectively bind heavy metals and promote their removal from the body, without disrupting the body’s store of essential metals like iron, calcium, and zinc.

  2. What kinds of metals does HOPO-001 chelate?
    HOPO-001 chelates and promotes the removal of a wide range of heavy metals from the body. These include lead, cadmium, and tin, as well most lanthanide and actinide elements. Of particular note are gadolinium, and the radioactive elements uranium, plutonium, and americium.

  3. Can HOPO-001 help children and communities impacted by lead or other heavy metal poisoning?
    Yes. Our mission is to improve the lives of people affected by lead poisoning.

  4. Can HOPO-001 remove gadolinium deposited from MRI contrast agents?
    Yes. In published preclinical studies HOPO-001 has proven far more effective than DTPA at removing gadolinium from the body.

  5. Does HOPO-001 cross the blood-brain barrier?
    Yes. The preclinical pharmacokinetics and biodistribution of 3,4,3-LI(1,2-HOPO) have been studied and it does cross the blood-brain barrier.

  6. Will HOPO-001 chelate deposited gadolinium that is “free” AND gadolinium still bound to a GBCA chelator? Based on the available data, yes, however at this point there is insufficient evidence to anticipate how effective it will be in these different scenarios.

  7. Can I purchase or obtain HOPO-001?
    At the moment, no. Please read this statement regarding the availability of our investigational drug.

  8. Can you answer questions or provide medical advice about metal toxicity or chelation treatments?
    No, we cannot provide any medical advice. Questions about exposure to or toxicity from heavy metals, courses of treatment, recommended chelators, symptoms related to heavy metal contamination, or any other heath-related topics should be directed to your physician.

  9. What can I do to stay informed about your progress?
    For shorter, more frequent updates, you can check the News page of our website, or follow us on Twitter. We also publish more comprehensive updates via our mailing list - please sign up here!

  10. When will you be starting clinical trials?
    HOPO-001, which is an oral formulation of 3,4,3-LI(1,2-HOPO), has been granted Investigational New Drug status by the FDA, meaning it has been shown to be both safe and effective in preclinical studies. We anticipate the first-in-human clinical trial to study safety and pharmacokinetics to begin in mid-2022.

  11. Can I sign up to participate in a clinical trial?
    We are not currently enrolling participants in any clinical trials. When we have funding and approval to begin enrolling clinical trials, we will make announcements on our website and via our mailing list - please consider signing up if you would like to be notified.

  12. I still have questions - who can I contact for more information?
    Our contact information is here. We regret that due to a large volume of inquiries, it may take us some time to reply depending on the nature of your message. We need to reiterate that HOPO-001 is not available for sale or distribution at this time.